![](/images/graphics-bg.png)
Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study
المؤلفون المشاركون
Cakir, Akin
Erden, Burak
Bolukbasi, Selim
Baş, Emine
المصدر
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-10-31
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Purpose.
To compare one-year treatment outcomes of intravitreal aflibercept (IVA) and intravitreal ranibizumab (IVR) for treatment of myopic choroidal neovascularization (mCNV).
Methods.
The medical records of a total of 30 eyes diagnosed with mCNV and underwent IVA or IVR treatment for a minimum one-year follow-up were studied retrospectively.
All the subjects had an axial length >26 mm and received a 1 + PRN (pro re nata) regimen IVA or IVR.
Best-corrected visual acuity (BCVA) and central macular thicknesses (CMT) on optical coherence tomography were evaluated before and after treatment.
Results.
There were 12 eyes in IVA group, with a mean age of 60.0 ± 10.2 years.
The mean BCVA significantly improved from baseline 1.54 ± 0.76 to 0.85 ± 0.61 and the mean CMT significantly decreased from baseline 384.3 ± 119.1 μm to 305.9 ± 75.4 μm at Month 12 (p:0.024 and p:0.011, respectively).
There were 18 eyes in IVR group, with a mean age of 57.4 ± 13.1 years.
The mean BCVA improved from baseline 1.14 ± 0.90 to 1.04 ± 0.93 and the mean CMT significantly decreased from baseline 366.5 ± 102.3 μm to 323.6 ± 103.6 μm at Month 12 after IVR (p:0.345 and p:0.011, respectively).
There was no significant difference between the groups in CMT changes in the study period (p:0.178), but IVA resulted in significantly better final visual gain (0.69 versus 0.09; p:0.006).
Conclusions.
Both IVA and IVR treatment modalities resulted in similar anatomical outcomes but IVA had better visual outcomes in treatment of mCNV.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Erden, Burak& Bolukbasi, Selim& Baş, Emine& Cakir, Akin. 2019. Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study. Journal of Ophthalmology،Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1186313
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Erden, Burak…[et al.]. Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study. Journal of Ophthalmology No. 2019 (2019), pp.1-6.
https://search.emarefa.net/detail/BIM-1186313
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Erden, Burak& Bolukbasi, Selim& Baş, Emine& Cakir, Akin. Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study. Journal of Ophthalmology. 2019. Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1186313
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1186313
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)